Abstract
With the discovery of RNA interference technology, small-interfering RNA (siRNA) has emerged as new powerful tool for gene therapy because of its high targeting specificity and selectivity. However, one of the limitations to successful gene therapy is the inability to monitor delivery of genes and therapeutic responses at the targeted site. Hence, a combinatorial approach of gene therapy with molecular imaging has been crucial in optimizing gene therapy. Recent advances in nanotechnology have made tremendous efforts to develop multifunctional nanoparticles that contain imaging and therapeutic agents together for image-guided therapy. The nanoparticles serve as contrast agents in imaging for disease detection with simultaneous delivery of therapeutics to cure the diseases. The therapy also helps to monitor the drug accumulation and assimilation in the body, thereby facilitating the evaluation of treatment effects. Here, we present an overview of polymer and lipid-based carriers for siRNA delivery, along with imaging agents as imageguided therapy, in the treatment of breast, lung, liver, ovarian, cervical, and prostate cancers.
Keywords: RNA interference, gene therapy, nanotechnology, imaging agents, cancer theragnosis.
Current Pharmaceutical Design
Title:Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy
Volume: 21 Issue: 31
Author(s): Yong-Dong Kim, Tae-Eun Park, Bijay Singh, Sushila Maharjan, Kye-Soo Cho, Kyoung Pyo Park, Yun-Jaie Choi, Rohidas B. Arote and Chong-Su Cho
Affiliation:
Keywords: RNA interference, gene therapy, nanotechnology, imaging agents, cancer theragnosis.
Abstract: With the discovery of RNA interference technology, small-interfering RNA (siRNA) has emerged as new powerful tool for gene therapy because of its high targeting specificity and selectivity. However, one of the limitations to successful gene therapy is the inability to monitor delivery of genes and therapeutic responses at the targeted site. Hence, a combinatorial approach of gene therapy with molecular imaging has been crucial in optimizing gene therapy. Recent advances in nanotechnology have made tremendous efforts to develop multifunctional nanoparticles that contain imaging and therapeutic agents together for image-guided therapy. The nanoparticles serve as contrast agents in imaging for disease detection with simultaneous delivery of therapeutics to cure the diseases. The therapy also helps to monitor the drug accumulation and assimilation in the body, thereby facilitating the evaluation of treatment effects. Here, we present an overview of polymer and lipid-based carriers for siRNA delivery, along with imaging agents as imageguided therapy, in the treatment of breast, lung, liver, ovarian, cervical, and prostate cancers.
Export Options
About this article
Cite this article as:
Kim Yong-Dong, Park Tae-Eun, Singh Bijay, Maharjan Sushila, Cho Kye-Soo, Park Pyo Kyoung, Choi Yun-Jaie, Arote B. Rohidas and Cho Chong-Su, Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/138161282131151013192327
DOI https://dx.doi.org/10.2174/138161282131151013192327 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytochrome P450 Retinoic Acid 4-Hydroxylase Inhibitors: Potential Agents for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Current Pharmaceutical Design Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling
Current Medicinal Chemistry An Overview of Compounds Derived from the Shikimate and Phenylpropanoid Pathways and Their Medicinal Importance
Mini-Reviews in Medicinal Chemistry Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Synthetic Vaccines: The Role of Adjuvants in Immune Targeting
Current Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Biomarkers for Colorectal Cancer: Identification Through Proteomics
Current Proteomics Omega-3 Polyunsaturated Fatty Acids and Cancer
Anti-Cancer Agents in Medicinal Chemistry Wnt Signaling and Prostate Cancer
Current Drug Targets Extraction, Chemical Composition, Antioxidant Property, and <i>In-vitro</i> Anticancer Activity of Silymarin from <i>Silybum marianum</i> on Kb and A549 Cell Lines
Current Drug Discovery Technologies Recent Therapeutic Advances for Treating Medulloblastoma: Focus on New Molecular Targets
CNS & Neurological Disorders - Drug Targets Current Advances in Antibody Immobilization on Different Surfaces and Beads
Current Proteomics Antisense Oligodeoxynucleotide Therapy for Prostate Cancer Targeting Antiapoptotic Genes Involved in the Mechanism Mediating Progression to Androgen Independence
Current Signal Transduction Therapy Skp2 Inhibitors: Novel Anticancer Strategies
Current Medicinal Chemistry Developments in Synthesis of the Anti-inflammatory Drug, Celecoxib: A Review
Recent Patents on Inflammation & Allergy Drug Discovery LHRH-Targeted Drug Delivery Systems for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Natural Products as Farnesoid X Receptor (FXR) Agonists: Their Interactions with FXR Ligand Binding Region
Mini-Reviews in Organic Chemistry Editorial [Hot Topic: Environmental Impacts on Enzymes Involved in Drug and Steroid Metabolism Guest Editor: R.H. Waring ]
Current Drug Metabolism Prospective Plant Based Anticancer Lead Molecules
Current Topics in Medicinal Chemistry